Teva Files Paragraph IV ANDA For Avapro

Law360, New York (July 20, 2004, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceuticals has filed an application to make a generic version of Sanofi-Synthelabo’s hypertension drug Avapro.

Teva filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification with the U.S. Food and Drug Administration for the marketing in the U.S.of a generic version of the drug Sanofi-Synthelabo said.

The filing does not challenge Sanofi-Synthelabo’s basic product patent that expires in 2011, but alleges only that the Teva formulation does not infringe the pharmaceutical formulation patent expiring in 2015, Sanofi-Synthelabo said....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.